Jove
Visualize
Contact Us

Related Experiment Videos

Purine analogs in marginal-zone lymphomas

S J Horning1

  • 1Division of Oncology, Stanford University Medical Center, Palo Alto, CA, USA.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|January 1, 1996
PubMed
Summary

Marginal-zone lymphomas, including MALT, MBCL, and splenic subtypes, have unique features. Treatment varies, with antibiotics effective for gastric MALT lymphomas and purine analogs showing promise.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Introduction: ASCO-ESMO consensus statement on quality cancer care.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by <sup>90</sup>Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499.

Leukemia·2016
Same author

The role of body mass index in survival outcome for lymphoma patients: US intergroup experience.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2007
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Hematology
  • Oncology
  • Immunopathology

Background:

  • Marginal-zone lymphomas (MZLs) are a distinct group within non-Hodgkin's lymphomas.
  • They possess unique immunohistochemical and cytogenetic profiles differentiating them from mantle-cell and follicular lymphomas.
  • MZLs encompass three main subtypes: extranodal mucosa-associated lymphoid tissue (MALT) lymphomas, nodal monocytoid B-cell (MBCL) lymphomas, and splenic marginal-zone lymphomas.

Purpose of the Study:

  • To delineate the classification and characteristics of marginal-zone lymphomas.
  • To describe the subtypes and their origins, particularly MALT lymphomas in extranodal sites.
  • To outline current and potential therapeutic strategies for these indolent lymphomas.

Main Methods:

  • Review of distinct immunohistochemical and cytogenetic features for classification.
  • Identification of MALT lymphomas in extranodal sites like the stomach, thyroid, and salivary glands.
  • Evaluation of therapeutic approaches including surgery, radiation, antibiotics, and purine analogs.

Main Results:

  • Gastric MALT lymphomas are frequently associated with Helicobacter pylori infection.
  • MBCL lymphomas share similarities with MALT lymphomas and can be composite.
  • Antibiotic therapy targeting H. pylori is effective for gastric MALT lymphomas, reducing the need for gastrectomy.
  • Purine analogs demonstrate potential as second-line therapy due to their efficacy against both dividing and resting lymphoid cells.

Conclusions:

  • Marginal-zone lymphomas are a heterogeneous group requiring specific diagnostic and therapeutic considerations.
  • H. pylori eradication is a key treatment for gastric MALT lymphomas.
  • Purine analogs represent a promising therapeutic option for indolent lymphomas, including MZLs.

Related Experiment Videos